The biopharmaceutical industry relies heavily on monoclonal antibodies (mAbs) for treating a wide range of diseases, from cancer to autoimmune disorders. Producing these complex molecules at scale requires sophisticated purification processes, and a key component of that process is chromatography. Specifically, multimodal chromatography is gaining prominence as a versatile technique for refining mAb-based products, offering improvements in impurity removal and overall efficiency. This approach is becoming increasingly important as manufacturers strive to meet stringent regulatory requirements and deliver high-quality therapeutics.
Traditionally, antibody purification has involved a series of chromatographic steps, often beginning with Protein A affinity chromatography for initial capture. However, subsequent polishing steps are crucial for removing aggregates, host cell proteins (HCPs), DNA, and other process-related impurities. Multimodal chromatography provides a powerful alternative or complement to traditional methods like ion exchange and hydrophobic interaction chromatography, often combining features of both into a single resin. This can streamline the purification workflow and reduce costs.
Understanding Multimodal Chromatography Mechanisms
Multimodal chromatography utilizes resins that incorporate multiple types of interaction mechanisms. As detailed in a recent review published by Wiley Online Library, these mechanisms can include ionic interactions, hydrophobic interactions, hydrogen bonding, and dipole-dipole interactions. The review provides a comprehensive comparison of commercially available resins, highlighting their unique properties, and applications. This versatility allows for tailored purification strategies based on the specific characteristics of the mAb and the impurities present.
The choice of resin is critical. Different resins exhibit varying affinities for different impurities. For example, a resin with both hydrophobic and ionic functionalities might effectively bind both aggregates and HCPs. By carefully selecting the resin and optimizing the mobile phase conditions (pH, salt concentration, etc.), manufacturers can achieve highly selective purification.
Addressing Antibody Aggregate Removal
One of the most significant challenges in mAb purification is the removal of aggregates. These aggregates can reduce efficacy and, more importantly, trigger unwanted immune responses in patients. A study published in Molecules in May 2025, focused specifically on antibody aggregate removal by multimodal chromatography, demonstrated the effectiveness of this technique in reducing aggregate levels. The research, conducted by Veronika Rupčíková and colleagues at the Slovak University of Technology, investigated the leverage of multimodal chromatography as a polishing step following affinity chromatography.
The study highlighted that multimodal chromatography can effectively separate aggregates from monomeric antibodies based on differences in their surface properties and hydrodynamic size. The researchers found that optimizing the mobile phase conditions, such as salt concentration and pH, was crucial for achieving optimal separation. This is particularly important because aggregates often exhibit increased hydrophobicity compared to monomeric antibodies, making them more susceptible to binding to hydrophobic ligands on the resin.
Strategies and Applications in Downstream Processing
The application of multimodal chromatography extends beyond aggregate removal. It can also be used for removing HCPs, DNA, and other process-related impurities. The strategy often involves employing multiple multimodal chromatography steps with different resin chemistries and mobile phase conditions to achieve a comprehensive purification profile. This sequential approach allows for the selective removal of a wider range of impurities.
advancements in resin technology are continually expanding the capabilities of multimodal chromatography. Newer resins are being designed with improved selectivity, binding capacity, and mechanical stability. These improvements translate to higher product yields, reduced process costs, and enhanced product quality. Technology Networks reports on mastering next-generation therapeutic antibody impurity removal, emphasizing the importance of these advancements.
The integration of process analytical technology (PAT) is also playing a key role in optimizing multimodal chromatography processes. PAT tools, such as online UV and conductivity sensors, provide real-time monitoring of the purification process, allowing for dynamic adjustments to maintain optimal performance. This data-driven approach enhances process control and reduces variability.
Looking ahead, the continued development of novel multimodal chromatography resins and the implementation of advanced process control strategies will further solidify its position as a cornerstone of mAb purification. The demand for high-quality biotherapeutics is only expected to grow, and multimodal chromatography will be essential for meeting that demand efficiently and reliably. The next key step for manufacturers will be to fully leverage the potential of these technologies to streamline their processes and reduce the cost of goods.
Have your own thoughts on the future of biopharmaceutical purification? Share your comments below, and feel free to share this article with your network.
